A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the patient with advanced colorectal cancer
Not Applicable
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000003164
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2) Pregnant or breast-feeding women 3) Severe mental disease 4) Systemic administration of corticosteroids 5) Continuous medication of flusitosine, fenitoin,and/or Warfarin 6) Other severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, regular use of insulin or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 7) Myocardial infarction within the past 6 months 8) Inadequate physical condition, as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method